Axios

The Food and Drug Administration seized thousands of pages of documents last week during an inspection of the San Fransisco headquarters of e-cigarette maker Juul, the agency said Tuesday.

The big picture: The FDA is taking a look at the marketing practices of the company, as it is concerned about the uptick in vaping among younger generations. Last month, the agency specifically called on Juul and four other e-cigarette makers to present plans that prove their products can be kept away from teenagers. The companies were given 60 days before the FDA said it would take further action, including the possible ban of flavored products.

The Trump administration has been touting the fact that Affordable Care Act coverage is on track for relatively modest premium increases next year in much of the country. But a new paper published in Health Affairs offers a reminder that Trump has not been a friend to the ACA’s exchanges.

By the numbers: In 2016, 93% of the country lived in a county where they'd have at least three insurers to choose from, if they wanted to buy coverage through the exchanges. This year, that's down to 60% of the population.

The U.S. Agency for International Development announced Monday that it has sent a disaster assistance response team (DART) to the Democratic Republic of the Congo to help contain the outbreak of the deadly Ebola virus.

Why it matters: While USAID and the Health and Human Services Department initially sent staff to the area during the Ebola outbreak in early August, this is the first deployment of an elite DART team, which indicates increased concern from U.S. officials.

Democrats are increasingly embracing "Medicare for All." Thing is, though, they don't necessarily agree about what that means.

Why it matters: Democrats haven't had to reconcile these competing visions ahead of the midterm elections, when the sheer number of candidates running for different offices has allowed everyone to stick to their own definition of a broadly popular term.

California Gov. Jerry Brown vetoed a bill late Sunday that would have, among other things, capped payments at lower Medicare rates for dialysis facilities that have financial ties to charities that subsidize patients' commercial insurance.

Why it matters: It's a huge win for dialysis companies like DaVita, and for and charities linked to the dialysis industry — like the American Kidney Fund, which lobbied heavily against the bill. Now the industry will look to defeat a midterm ballot measure that would place a much more restrictive cap on dialysis clinics' profits.

The conventional wisdom is that corporate America has a renewed, almost crisis-level concern about rising health costs. But, in a puzzle I am struggling to solve, the data don’t suggest a basis for a new level of urgency about health costs in corporate America.

Why it matters: In fact, just the opposite is true. There's just not that much change — so any solution that's designed for a crisis will probably miss the mark or could unnecessarily harm workers.